Research
Hormonal
Orforglipron has advanced through Phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability.
Practitioners can consider Orforglipron as an effective option for managing hemoglobin A1c and body weight.
StrongSupportsmedium confidence
Orforglipron has notably advanced through Phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability.
Why this rating
Based on the mention of Phase 3 clinical development.
Source
Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies
Héctor Iván Saldívar-Cerón et al. · Scientia Pharmaceutica · 2025
reviewCited 9×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →